Project Grant R01HL166832
Award Date
9/25/24
Completion Date
6/30/29
Dollars Obligated
$704K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA program 93.837 Cardiovascular Diseases Research is providing $807,948 to support a study on the genetics of left ventricular hypertrophy (LVH) and associated cardiac phenotypes. The primary awardee, The Medical College of Wisconsin, Inc. (MCW), will utilize whole genome sequencing data from the NHLBI TOPMed program to conduct association analyses and identify genetic variants related to LVH....
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $694,754 to The Washington University in St. Louis to conduct research on understanding the molecular and cellular mechanisms underlying cardiomyopathies and identifying potential therapeutic interventions. The key objectives are to: 1) determine if patient mutations in the troponin gene can be grouped based on common molecular...
This $767,579 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to leverage large-scale biobanks to discover and define rare variant effects in hypertrophic cardiomyopathy (HCM). The key objectives are to: Define the contribution and phenotypic manifestations of established HCM disease genes in diverse, non-referral populations. Assess the pathogenicity of candidate HCM genes and establish a platform to evaluate variants of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $135,840 to the University of Washington from September 1, 2024 to August 31, 2026. The project will investigate the mechanisms of cardiac contractile dysfunction across multiple scales using a combined computational and experimental platform. Specifically, the work will focus on how structural perturbations to the myosin protein affect its...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $100,480 to The University of Texas Southwestern Medical Center to conduct research on understanding the roles of nuclear envelope proteins and DNA damage in cardiomyopathy. The key objectives of this 2-year research project are to: 1) characterize the DNA damage and DNA damage response in cardiomyocytes carrying LEMD2 mutations...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to understand the mechanisms of signaling interaction between the endocardium and myocardium during heart development and trabecular formation. The $675,606 award to the University of Houston System aims to determine the ultrastructure and function of "signaling bridges" - nanotube-like structures that...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,400 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Michigan. The 5-year grant, which commenced on May 15, 2025, supports research by Dr. Joshua Meisner, a pediatric cardiologist and physician-scientist, to elucidate the mechanical and metabolic pathways underlying hypertrophic cardiomyopathy (HCM) caused by MYBPC3 gene mutations. The research aims to develop...
This $506,984 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of the LRP1 gene in the development of congenital heart disease (CHD). The primary objectives are to: Examine the deployment and migration of cardiac neural crest cells (CNCCs) and their dependence on LRP1 using in vitro and in vivo cell lineage fate mapping analysis. Investigate the cellular and molecular...
This federal Project Grant award of $2,249,307, provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to study the premature maturation arrest of pluripotent-derived cardiomyocytes (PSC-CMs) and develop strategies to overcome this issue. The project will leverage a high-resolution single cell transcriptome map of endogenous cardiomyocyte maturation to identify a critical gene regulatory network underlying the maturation failure in PSC-CMs....